Patient factors, including Medicaid or Medicare Advantage, comorbid substance use disorder, medical comorbidities, and prescription-related factors, are associated with opioid overdose, according to a...
FDA recently approved an update to the prescribing information for Kite’s Yescarta to include prophylactic corticosteroids across all approved indications.
The agency first approved Yescarta in...
Pfizer recently announced that it will appoint William Pao, MD, PhD, as executive vice president and chief development officer.
Effective March 2022, Pao will replace Rod Mackenzie, who recently...
FDA fully approves Moderna’s mRNA COVID-19 vaccine, Spikevax, for individuals 18 years of age and older.
"The full licensure of Spikevax in the US now joins that in Canada, Japan, the European...
Modern and IAVI recently dosed the first two patients in a clinical trial of experimental HIV vaccine antigens at the George Washington University (GWU) School of Medicine and Health Sciences.
The...
Most pregnant and postpartum women with opioid use disorder (OUD) in US jails do not receive medication that is standard of care, a JAMA Network Open study found.
The cross-sectional study surveyed...
FDA recently accepted for review Regeneron’s biologics license application for its PD-1 inhibitor, Libtayo, in combination with chemotherapy to treat advanced non-small cell lung cancer...
The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania Gene Therapy Program (GCP) recently collaborated to advance the discovery and manufacturing of gene therapies.
The...
Moderna and Carisma Therapeutics recently entered into an agreement to discover, develop, and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer...
Pfizer recently announced that its COVID-19 treatment, Paxlovid, maintained plasma concentrations many-fold times higher than the amount required to prevent the Omicron variant from replicating in...
AstraZeneca recently collaborated with Scorpion Therapeutics to discover, develop, and commercialize precision medicines against previously undruggable targets.
The companies will focus on a class of...
Pfizer and Beam Therapeutics recently entered into a four-year collaboration focused on in vivo base editing programs to generate precision medicine for rare diseases of the liver, muscle, and central...
GSK recently appointed Tony Wood as chief executive officer (CSO), replacing current CSO Hal Barron.
Wood, a highly respected scientist and one of the world’s pre-eminent chemists, has over 30...
Bristol Myers Squibb and Century Therapeutics recently collaborated to develop and commercialize up to four engineered natural killer (iNK) and/or allogeneic cell therapies for hematologic malignancies...
Pfizer recently announced positive top-line results from a Phase 3 trial studying its COVID-19 vaccine combined with its pneumococcal 20-valent conjugate vaccine, Prevnar 20.
The study, B74710126,...
Johnson & Johnson Medical Device Companies (JJMDC) recently tapped Microsoft to expand its secure and compliant digital surgery ecosystem.
Microsoft Cloud will help JJDMC drive innovation that...
Sanofi and Exscientia recently entered into a research collaboration and license agreement to develop 15 novel small molecule drug candidates across oncology and immunology.
The companies will...
Real-world evidence recently confirmed that Johnson & Johnson’sJohnson’s COVID-19 vaccine provides long-lasting protection against breakthrough infections, hospitalizations, and ICU...
Eli Lilly & Company recently acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to develop nucleic acid products.
The companies will initially...
Moderna recently dosed the first participant in a Phase 1 study of its mRNA vaccine, mRNA-1189, for Epstein-Barr Virus (EBV).
The Eclipse study will enroll nearly 270 participants 18 to 30 years of...
